osimertinib
astrazeneca
['sclc', 'nsclc', 'osimertinib']
neoadjuvant osimertinib (1-2 months) in 27 pts with resectable egfr mutant nsclc #asco23 #ucsf mpr 15%, 89% pts r0 surgery 11% pts finally received chemorx . co-mutations in rbm10 may decrease apoptosis and efficacy. 
MD, PhD - Thoracic Oncologist. Precision Medicine Consultant & Co-Founder PxMedica and Medical Consultant @bradfordhill_cl.